Meet Kanika, a 29-year-old female, whose career has been impacted by RA.1
‘Designing jewellery is my passion and I’ve been able to make a career out of it. If I don’t find a solution soon, I’m afraid RA will get in the way of me being able to take things further’.
‘It’s worrying that after taking MTX for 2 years my symptoms aren’t getting better.1 I’m now on steroids and NSAIDs, but I’m not sure they’re having an impact on my symptoms’.
TNFi treatment discontinuation is usually due to loss/lack of efficacy or incidence of AEs.2,3
Note: This is a hypothetical case for representation purpose only.
Young RA patients such as Kanika benefit from long-term treatment with Enbrel®2,4,5
From a meta-analysis of 170 observational studies that evaluated a total of 270,000 patients with RA.2
TNFi Drug Survival Rate2,§
Adapted from Emery P, et al. 2019.
Please consult the LPD for contraindications, warnings, precautions and other important safety information.
Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which Enbrel® (etanercept) could be considered.
*From a meta-analysis of 170 observational studies that evaluated a total of 270,000 patients with RA. After >12 months of follow-up, more patients with RA receiving Enbrel® remained on treatment compared with other TNFi.1
Study design: Emery P, et al. 2019.
A systematic literature review and meta-analysis was conducted. The aim of the analysis was to: 1) identify all publications reporting the long-term drug survival of Enbrel®, adalimumab, infliximab, certolizumab pegol and golimumab using observational data from patients with RA and 2) evaluate rates of drug survival and discontinuation after ≥12 months of follow-up.2
In total, 170 publications were identified (133 full articles and 37 conference abstracts), all of which described non-randomised, observational studies.2
†From a population-based cohort of 583 patients with RA followed over 12 years in an Italian registry. Enbrel® showed a 52.5% drug survival rate at 12 years, which was significantly higher than those for adalimumab and infliximab.5
‡From an analysis of RA patients (558 early RA patients, 714 long-standing RA patients) who had participated in one or more Enbrel® ‘parent’ RCT, and subsequently entered long-term, open-label trials during which they received Enbrel® 25 mg BIW. ACR20/50/70 improvements were maintained over 11 years in both early and long-standing RA patients.4
ACR, American College of Rheumatology; AE, adverse event; AS, ankylosing spondylitis; MTX, methotrexate-inadequate responder; NR, not reported; RA, rheumatoid arthritis; RCT, randomised controlled trial; TNFi, tumour necrosis factor inhibitor; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; PsO, psoriasis; SmPC, summary of product characteristics.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.